Potential treatment of COVID-19

Following the first reported cases of pneumonia of unknown etiology at the end of 2019 in Wuhan city, Hubei province, China, the causative agent was demonstrated to be a new coronavirus that has not been defined in humans before. The World Health Organization (WHO) named this virus as severe acute r...

Full description

Bibliographic Details
Main Authors: Omer Ayten, Cengiz Özdemir, Ülkü Aka Aktürk, Nazan Şen
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2020-01-01
Series:Eurasian Journal of Pulmonology
Subjects:
Online Access:http://www.eurasianjpulmonol.com/article.asp?issn=2148-5402;year=2020;volume=22;issue=4;spage=35;epage=44;aulast=Ayten
id doaj-a45816ceaa2e4cfa9732417dd8beb9d7
record_format Article
spelling doaj-a45816ceaa2e4cfa9732417dd8beb9d72021-01-08T03:17:34ZengWolters Kluwer Medknow PublicationsEurasian Journal of Pulmonology 2148-54022148-54022020-01-01224354410.4103/ejop.ejop_61_20Potential treatment of COVID-19Omer AytenCengiz ÖzdemirÜlkü Aka AktürkNazan ŞenFollowing the first reported cases of pneumonia of unknown etiology at the end of 2019 in Wuhan city, Hubei province, China, the causative agent was demonstrated to be a new coronavirus that has not been defined in humans before. The World Health Organization (WHO) named this virus as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the disease caused by the virus as coronavirus disease-19 (COVID-19). The disease spread rapidly to other countries through human-to-human transmission, and WHO declared a pandemic on March 11, 2020. As of April 2020, the number of individuals infected with SARS-CoV-2 and COVID-19 related deaths continue to increase rapidly worldwide. The main reason for the increase in the rate of infection is person-to-person transmission, while the main reason for the increase in mortality rate is the lack of a proven medical treatment specific to COVID-19 and the severe course of the disease in the elderly with low immunity. While a vast majority of individuals infected with SARS-CoV-2 are asymptomatic or recover after displaying mild symptoms, hospitalization is required in 14% of cases and severe disease requiring intensive care admission is seen in 5% of the infected individuals. WHO and national guidelines do not make clear recommendations regarding treatments for symptomatic patients. Currently, there is no vaccine or specific antiviral treatment for COVID-19, however supportive care, isolation and protective measures and experimental drugs/treatments are being used for the management of COVID-19. Medical treatments being used for COVID-19, aim to prevent the entry of the virus into the cell, to inhibit or reduce its replication, and to suppress the increased inflammatory response. In addition, “convalescent” plasma, which includes antibodies of patients who were completely recovered from the infection, is among the treatment options.http://www.eurasianjpulmonol.com/article.asp?issn=2148-5402;year=2020;volume=22;issue=4;spage=35;epage=44;aulast=Aytencoronavirus disease-2019potential treatmentsevere acute respiratory syndrome-coronavirus 2
collection DOAJ
language English
format Article
sources DOAJ
author Omer Ayten
Cengiz Özdemir
Ülkü Aka Aktürk
Nazan Şen
spellingShingle Omer Ayten
Cengiz Özdemir
Ülkü Aka Aktürk
Nazan Şen
Potential treatment of COVID-19
Eurasian Journal of Pulmonology
coronavirus disease-2019
potential treatment
severe acute respiratory syndrome-coronavirus 2
author_facet Omer Ayten
Cengiz Özdemir
Ülkü Aka Aktürk
Nazan Şen
author_sort Omer Ayten
title Potential treatment of COVID-19
title_short Potential treatment of COVID-19
title_full Potential treatment of COVID-19
title_fullStr Potential treatment of COVID-19
title_full_unstemmed Potential treatment of COVID-19
title_sort potential treatment of covid-19
publisher Wolters Kluwer Medknow Publications
series Eurasian Journal of Pulmonology
issn 2148-5402
2148-5402
publishDate 2020-01-01
description Following the first reported cases of pneumonia of unknown etiology at the end of 2019 in Wuhan city, Hubei province, China, the causative agent was demonstrated to be a new coronavirus that has not been defined in humans before. The World Health Organization (WHO) named this virus as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the disease caused by the virus as coronavirus disease-19 (COVID-19). The disease spread rapidly to other countries through human-to-human transmission, and WHO declared a pandemic on March 11, 2020. As of April 2020, the number of individuals infected with SARS-CoV-2 and COVID-19 related deaths continue to increase rapidly worldwide. The main reason for the increase in the rate of infection is person-to-person transmission, while the main reason for the increase in mortality rate is the lack of a proven medical treatment specific to COVID-19 and the severe course of the disease in the elderly with low immunity. While a vast majority of individuals infected with SARS-CoV-2 are asymptomatic or recover after displaying mild symptoms, hospitalization is required in 14% of cases and severe disease requiring intensive care admission is seen in 5% of the infected individuals. WHO and national guidelines do not make clear recommendations regarding treatments for symptomatic patients. Currently, there is no vaccine or specific antiviral treatment for COVID-19, however supportive care, isolation and protective measures and experimental drugs/treatments are being used for the management of COVID-19. Medical treatments being used for COVID-19, aim to prevent the entry of the virus into the cell, to inhibit or reduce its replication, and to suppress the increased inflammatory response. In addition, “convalescent” plasma, which includes antibodies of patients who were completely recovered from the infection, is among the treatment options.
topic coronavirus disease-2019
potential treatment
severe acute respiratory syndrome-coronavirus 2
url http://www.eurasianjpulmonol.com/article.asp?issn=2148-5402;year=2020;volume=22;issue=4;spage=35;epage=44;aulast=Ayten
work_keys_str_mv AT omerayten potentialtreatmentofcovid19
AT cengizozdemir potentialtreatmentofcovid19
AT ulkuakaakturk potentialtreatmentofcovid19
AT nazansen potentialtreatmentofcovid19
_version_ 1724345502594498560